文献速递前列腺癌

转移性去势抵抗性前列腺癌的基因组检测:临床医生实用指南

Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
PubMed 文献 · Eur Urol · 2021-01-23

该综述回顾了近15年PubMed文献、会议资料和指南,总结mCRPC的基因组改变及检测现状。mCRPC存在可靶向的分子改变,国际指南推荐晚期/高危PC患者不论家族史均行胚系和/或体细胞检测,以识别同源重组修复基因突变或错配修复缺陷/微卫星不稳定者。

要点

  • mCRPC肿瘤携带可靶向的分子改变,如PD-1抑制剂、PARP抑制剂、酪氨酸激酶抑制剂相关靶点。
  • 肿瘤组织DNA二代测序可识别胚系检测无法发现的体细胞改变。
  • 指南推荐晚期/高危PC患者不论家族史均行胚系和/或体细胞检测。

核心结论

  • mCRPC的基因组检测可提供预后、预测和耐药生物标志物信息。
  • 推荐对晚期PC男性常规进行基因组检测以指导管理和治疗决策。

研究设计与样本

  • 综述近15年PubMed文献、科学会议论文集和已发表指南。
  • 纳入mCRPC基因组改变识别技术的开发、检测和验证、分子特征描述及基因靶向治疗试验报告。

主要发现

  • mCRPC肿瘤携带可能作为治疗靶点的分子改变,多种针对这些改变的治疗正在开发中。
  • 肿瘤组织DNA二代测序可识别胚系检测无法发现的体细胞改变。
  • 正在评估微创体细胞检测方法,如游离循环肿瘤DNA测序。

关键数值与推荐

  • 当前国际指南推荐晚期和/或高危PC男性不论家族史均行胚系和/或体细胞检测。
  • 检测旨在识别同源重组修复基因突变或错配修复缺陷/微卫星不稳定者,分别可能适合PARP抑制剂或帕博利珠单抗治疗。

临床怎么用

  • 对晚期PC男性常规进行基因组检测以指导管理和治疗决策。
  • 利用检测识别可能从PARP抑制剂或帕博利珠单抗治疗中获益的患者。

局限性

  • 将检测纳入临床实践仍具挑战性。
  • 微创体细胞检测方法(如游离循环肿瘤DNA测序)仍在评估中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Genomic testing is becoming increasingly important in patients with advanced prostate cancer (PC) and is being incorporated in clinical practice to guide treatment. OBJECTIVE: To review the current understanding of genomic alterations and the status of genomic testing in patients with metastatic castration-resistant PC (mCRPC), and the potential use of genomic tests in clinical practice. EVIDENCE ACQUISITION: We reviewed recent publications (past 15 yr) from PubMed, proceedings of scientific conferences, and published guidelines. Reports on mCRPC in the following areas were selected: development, testing, and validation of techniques for identifying genomic alterations; molecular characterization; and trials of genetically targeted therapies. EVIDENCE SYNTHESIS: mCRPC tumors harbor molecular alterations that are possible targets for treatment, and a number of therapies are in development to exploit these alterations (eg, PD-1 inhibitors, PARP inhibitors, tyrosine kinase inhibitors). Next-generation sequencing of DNA from tumor tissue can identify somatic alterations that would not be identified by germline testing. Work is ongoing to evaluate the use of less invasive somatic testing methods (eg, sequencing of cell-free circulating tumor DNA). Current international guidelines recommend germline and/or somatic testing for men with advanced and/or high-risk PC regardless of family history to identify those with homologous recombination repair gene mutations or mismatch repair defects/microsatellite instability who may be eligible for treatment with a PARP inhibitor or pembrolizumab, respectively. CONCLUSIONS: Genomic testing for mCRPC may provide information on prognostic, predictive, and resistance biomarkers. Although the incorporation of testing into clinical practice remains challenging, routine genomic testing of men with advanced PC is recommended to guide management and treatment decisions. PATIENT SUMMARY: Similar to many cancers, prostate cancer is caused by defects in the cancer's DNA, which are called genetic or genomic defects. New treatments targeting these defects are approved for metastatic castration-resistant prostate cancer. Specific new tests are under development to detect these potentially treatable genetic defects.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Merseburger AS, Waldron N, Ribal MJ, et al. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. Eur Urol. 2021. PMID: 33494937. doi:10.1016/j.eururo.2020.12.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。